LCM
ASMB icon

Laurion Capital Management’s Assembly Biosciences ASMB Stock Holding History

Laurion Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,167
Closed -$663K – 1620
2017
Q1 		$663K Buy
+2,167
New +$532K 0.01% 840

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Laurion Capital Management's ASMB Position: Q2 2017 in Review

Laurion Capital Management sold out of Assembly Biosciences (ASMB) in Q2 2017, closing a stake of 2,167 shares — an estimated $663K sold.

Laurion Capital Management first reported a position in ASMB in Q1 2017 and held it in 1 quarter. The position peaked at $663K in Q1 2017. 65 funds tracked by Wall St. Rank hold ASMB as of Q2 2017.

  • Laurion Capital Management reported no remaining Assembly Biosciences position as of Q2 2017 after selling out during the quarter.
  • Laurion Capital Management sold 2,167 Assembly Biosciences shares in Q2 2017, an estimated $663K.
  • Laurion Capital Management first reported a position in Assembly Biosciences in Q1 2017 and held it in 1 quarter.
  • Laurion Capital Management's Assembly Biosciences position peaked at $663K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2017.

Based on Laurion Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.